CAS NO: | 491871-58-0 |
规格: | ≥98% |
包装 | 价格(元) |
2mg | 询价 |
5mg | 询价 |
10mg | 询价 |
25mg | 询价 |
50mg | 询价 |
100mg | 询价 |
250mg | 询价 |
500mg | 询价 |
Molecular Weight (MW) | 367.2 |
---|---|
Formula | C18H11BrN2O2 |
CAS No. | 491871-58-0 |
Storage | -20℃ for 3 years in powder form |
-80℃ for 2 years in solvent | |
Solubility (In vitro) | DMSO: ≥ 52 mg/mL |
Water: <1 mg/mL | |
Ethanol: <1 mg/mL | |
Solubility (In vivo) | OC1=C(C(N2)=CC(C3=CC=CC=C3)=C(C#N)C2=O)C=C(Br)C=C1 |
Synonyms | TCS PIM 1 1; TCS-PIM-1 1; TCS PIM-1-1; SC-204330; SC 204330; SC204330 |
In Vitro | In vitro activity: TCS PIM-1 1, also known as sc-204330, is a highly potent substituted pyridone and selective ATP-competitive inhibitor of Pim-1 kinase with IC50 of 50 nM, it displays good selectivity over Pim-2 and MEK1/MEK2(IC50s>20,000 nM). TCS PIM-1 1 bound convincingly within the ATP-binding site of Pim-1 suggesting an ATP-competitive inhibitory mechanism. Pim-1 kinase has been implicated in inflammatory bowel disease (IBD). Therefore, Pim-1 inhibitor (PIM-Inh) such as TCS PIM-1 1 has potential for the treatment of IBD. Structural requirements for in vitro activity are outlined as well as a complex crystal structure with TCS PIM-1 1. A hydrogen bond matrix involving the Pim-1 inhibitor, two water molecules, and the catalytic core, together with a potential weak hydrogen bond between an aromatic hydrogen on the R(1) phenyl ring and a main-chain carbonyl of Pim-1, accounts for the overall potency of this inhibitor. Kinase Assay: TCS PIM-1 1, also known as sc-204330, is a highly potent substituted pyridone and selective ATP-competitive inhibitor of Pim-1 kinase with IC50 of 50 nM, it displays good selectivity over Pim-2 and MEK1/MEK2(IC50s>20,000 nM). Cell Assay: Pim-1 kinase inhibitor could attenuate IBD by promoting T-cell differentiation into Foxp3+ regulatory T-cells and is a promising agent for IBD therapy. |
---|---|
In Vivo | Mouse model of IBD was established by the treatment with trinitrobenzene sulphonic acid (TNBS). The results showed that disease activity index score was significantly decreased, colon length was significantly increased while Wallace score and pathological score were significantly decreased after PIM-Inh treatment compared to TNBS model group. In addition, GATA3 and ROR-γt mRNA and protein levels significantly increased but Foxp3 mRNA and protein levels significantly decreased in mice with TNBS treatment compared to mice without TNBS treatment. Administration of PIM-Inh caused significant decreases in GATA3, T-bet and ROR-γt mRNA and protein levels as well as significant increases in FOXP3 mRNA and protein levels. |
Animal model | Mouse model of IBD |
Formulation & Dosage | |
References | Clin Res Hepatol Gastroenterol. 2018 Sep;42(4):382-386. |
维奥蛋白资源库 - 中文蛋白资源 CopyRight © 2010-2025 |